Who Paid My Doc
Besponsa
Biological Oncology
NDC 0008-0100-01
General payments
$938,748
Research payments
$164,054,946
Through program year 2025, $938,748 in general payments and $164,054,946 in research payments were reported against Besponsa (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $8,584 | 49 |
| 2025 | Research | $31,796,088 | 63 |
| 2024 | General | $57,626 | 587 |
| 2024 | Research | $17,323,489 | 61 |
| 2023 | General | $144,564 | 3,495 |
| 2023 | Research | $12,593,353 | 78 |
| 2022 | General | $121,016 | 1,834 |
| 2022 | Research | $20,555,615 | 98 |
| 2021 | General | $148,258 | 726 |
| 2021 | Research | $35,617,671 | 122 |
| 2020 | General | $104,744 | 288 |
| 2020 | Research | $31,068,953 | 133 |
| 2019 | General | $353,956 | 1,410 |
| 2019 | Research | $15,099,777 | 51 |
Breakdown
The top 5 of 40 recipients; each share is of general payments naming this product in 2025.
The top 5 of 13 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 9 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
8,389 general · 606 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.